The Clinical Investigations Support Office (CISO) was established to provide investigators at the USC/Norris Comprehensive Cancer Center services, technologies and scientific consultation to enhance scientific productivity and foster interdisciplinary interaction and research. CISO is a centralized organization of individuals with specific and specialized roles in clinical trials development and administration. CISO provides a centralized administration for protocol development, review, prioritization, regulatory compliance, study conduct and monitoring and quality assurance. This shared resource has two components: a centralized Protocol Administration Unit and a Research Nursing/Data Management Unit. The centralized administration of clinical research activities is critical to the efficient conduct of clinical trials at the Cancer Center. The CISO protocol and data management system provides the centralized support services necessary for the conduct of externally- funded and internally peer-reviewed and monitored research clinical trials. CISO is tightly integrated with the operations of the Clinical Investigations Committee and the Quality Assurance Committee. CISO maintains all protocols and regulatory documents, distributes protocols, provides centralized data quality control and oversight, and maintenance of protocols databases. The Research Nursing/Data Management Unit provides the centralized function of advising and assisting investigators in patient eligibility assessments, data quality control and oversight. CISO occupies a suite of offices located on the 7th floor o the Topping Tower and satellite space located in proximity to patient treatment areas at the Los Angeles County+USC Medical Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA014089-26S1
Application #
6504880
Study Section
Project Start
2001-04-06
Project End
2001-11-30
Budget Start
Budget End
Support Year
26
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Southern California
Department
Type
DUNS #
041544081
City
Los Angeles
State
CA
Country
United States
Zip Code
90033
Miller, Kimberly A; Ramirez, Cynthia N; Wojcik, Katherine Y et al. (2018) Prevalence and correlates of health information-seeking among Hispanic and non-Hispanic childhood cancer survivors. Support Care Cancer 26:1305-1313
Liu, Minmin; Zhang, Lian; Li, Hongtao et al. (2018) Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma. Hepatology 68:1412-1428
Tobin, Jessica; Allem, Jon-Patrick; Slaughter, Rhona et al. (2018) Posttraumatic growth among childhood cancer survivors: Associations with ethnicity, acculturation, and religious service attendance. J Psychosoc Oncol 36:175-188
Belic, Jelena; Graf, Ricarda; Bauernhofer, Thomas et al. (2018) Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. Int J Cancer 143:1236-1248
Iriondo, Oihana; Liu, Yarong; Lee, Grace et al. (2018) TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun 9:1994
Schaal, Justin B; Maretzky, Thorsten; Tran, Dat Q et al. (2018) Macrocyclic ?-defensins suppress tumor necrosis factor-? (TNF-?) shedding by inhibition of TNF-?-converting enzyme. J Biol Chem 293:2725-2734
Naseem, Madiha; Barzi, Afsaneh; Brezden-Masley, Christine et al. (2018) Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 66:15-22
Robison, Nathan J; Yeo, Kee Kiat; Berliner, Adrian P et al. (2018) Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. J Neurooncol 138:199-207
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48

Showing the most recent 10 out of 842 publications